ARCAD-Asia倡议:利用昨天的数据为明天服务

Y. Takeda , T. Misumi , H. Bando , M. Suzuki , M. Wakabayashi , E. Oki , K. Yamazaki , Y. Kakeji , K. Shitara , M. Terashima , M. Raeisi , Y. Maehara , A. Ohtsu , T. Andre , A. de Gramont , Q. Shi , T. Yoshino , ARCAD Collaborators
{"title":"ARCAD-Asia倡议:利用昨天的数据为明天服务","authors":"Y. Takeda ,&nbsp;T. Misumi ,&nbsp;H. Bando ,&nbsp;M. Suzuki ,&nbsp;M. Wakabayashi ,&nbsp;E. Oki ,&nbsp;K. Yamazaki ,&nbsp;Y. Kakeji ,&nbsp;K. Shitara ,&nbsp;M. Terashima ,&nbsp;M. Raeisi ,&nbsp;Y. Maehara ,&nbsp;A. Ohtsu ,&nbsp;T. Andre ,&nbsp;A. de Gramont ,&nbsp;Q. Shi ,&nbsp;T. Yoshino ,&nbsp;ARCAD Collaborators","doi":"10.1016/j.esmogo.2023.08.006","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>In clinical oncology, it is widely recognized that data sharing and the integration of completed clinical trials can promote research and development (R&amp;D). The Foundation Aide et Recherche en Cancérologie Digestive (ARCAD) database project was initiated in Europe and the United States in 2006. Approximately 40 000 individual patient data (IPD) for metastatic colorectal cancer were collected and constructed as an integrated database.</p></div><div><h3>Materials and methods</h3><p>ARCAD-Asia was launched in 2021 and has been actively collecting Asian clinical trials. In addition, ARCAD-Asian data were periodically transferred to the Mayo Clinic, and IPD was integrated into the ARCAD database. Finally, all data were shared with three data centers, ARCAD-Asia and ARCAD, located in Europe, the United States, and Japan. We have developed a reproducible and reliable data conversion procedure based on the methodology established by ARCAD.</p></div><div><h3>Results</h3><p>From September 2021 to April 2023, 2318 IPD from four first-line, two second-line, and three third-line trials for metastatic colorectal cancer were integrated and stored in ARCAD-Asia. By autumn 2023, three more trials (1565 IPD) will be included, resulting in 12 trials (3883 IPD) in the Asia database. These are transferred and shared with ARCAD. After integrating Asian data, the ARCAD database contained 70 trials with ∼50 000 IPD.</p></div><div><h3>Conclusions</h3><p>Based on our active collaboration, ARCAD-Asia was established, and a global integrated database was constructed. As a next step, we will continue to collect Asian IPD and expand the cancer types, leading to a more comprehensive and available global database.</p></div>","PeriodicalId":100490,"journal":{"name":"ESMO Gastrointestinal Oncology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949819823000080/pdfft?md5=d6e0d515d9164d2352dde9012468c8a0&pid=1-s2.0-S2949819823000080-main.pdf","citationCount":"0","resultStr":"{\"title\":\"ARCAD-Asia initiative: leveraging yesterday’s data for tomorrow\",\"authors\":\"Y. Takeda ,&nbsp;T. Misumi ,&nbsp;H. Bando ,&nbsp;M. Suzuki ,&nbsp;M. Wakabayashi ,&nbsp;E. Oki ,&nbsp;K. Yamazaki ,&nbsp;Y. Kakeji ,&nbsp;K. Shitara ,&nbsp;M. Terashima ,&nbsp;M. Raeisi ,&nbsp;Y. Maehara ,&nbsp;A. Ohtsu ,&nbsp;T. Andre ,&nbsp;A. de Gramont ,&nbsp;Q. Shi ,&nbsp;T. Yoshino ,&nbsp;ARCAD Collaborators\",\"doi\":\"10.1016/j.esmogo.2023.08.006\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>In clinical oncology, it is widely recognized that data sharing and the integration of completed clinical trials can promote research and development (R&amp;D). The Foundation Aide et Recherche en Cancérologie Digestive (ARCAD) database project was initiated in Europe and the United States in 2006. Approximately 40 000 individual patient data (IPD) for metastatic colorectal cancer were collected and constructed as an integrated database.</p></div><div><h3>Materials and methods</h3><p>ARCAD-Asia was launched in 2021 and has been actively collecting Asian clinical trials. In addition, ARCAD-Asian data were periodically transferred to the Mayo Clinic, and IPD was integrated into the ARCAD database. Finally, all data were shared with three data centers, ARCAD-Asia and ARCAD, located in Europe, the United States, and Japan. We have developed a reproducible and reliable data conversion procedure based on the methodology established by ARCAD.</p></div><div><h3>Results</h3><p>From September 2021 to April 2023, 2318 IPD from four first-line, two second-line, and three third-line trials for metastatic colorectal cancer were integrated and stored in ARCAD-Asia. By autumn 2023, three more trials (1565 IPD) will be included, resulting in 12 trials (3883 IPD) in the Asia database. These are transferred and shared with ARCAD. After integrating Asian data, the ARCAD database contained 70 trials with ∼50 000 IPD.</p></div><div><h3>Conclusions</h3><p>Based on our active collaboration, ARCAD-Asia was established, and a global integrated database was constructed. As a next step, we will continue to collect Asian IPD and expand the cancer types, leading to a more comprehensive and available global database.</p></div>\",\"PeriodicalId\":100490,\"journal\":{\"name\":\"ESMO Gastrointestinal Oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-11-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2949819823000080/pdfft?md5=d6e0d515d9164d2352dde9012468c8a0&pid=1-s2.0-S2949819823000080-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ESMO Gastrointestinal Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2949819823000080\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ESMO Gastrointestinal Oncology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2949819823000080","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

在临床肿瘤学领域,人们普遍认为数据共享和已完成临床试验的整合可以促进研究与开发(R&D)。2006年,在欧洲和美国启动了癌症研究基金会(ARCAD)数据库项目。收集了大约40000例转移性结直肠癌的个体患者数据(IPD),并构建了一个综合数据库。sarcad - asia于2021年启动,一直在积极收集亚洲临床试验。此外,ARCAD- asian数据定期传输到Mayo Clinic, IPD被整合到ARCAD数据库中。最后,所有数据都与位于欧洲、美国和日本的三个数据中心ARCAD- asia和ARCAD共享。我们根据ARCAD建立的方法开发了可重复和可靠的数据转换程序。从2021年9月到2023年4月,来自转移性结直肠癌的4个一线、2个二线和3个三线试验的2318个IPD被整合并保存在ARCAD-Asia。到2023年秋季,将再纳入三个试验(1565 IPD),从而使亚洲数据库中有12个试验(3883 IPD)。这些数据被传输并与ARCAD共享。在整合亚洲数据后,ARCAD数据库包含70项试验,IPD约为5万。结论在双方积极合作的基础上,建立了ARCAD-Asia数据库,并建立了全球综合数据库。下一步,我们将继续收集亚洲IPD并扩大癌症类型,从而建立一个更全面和可用的全球数据库。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
ARCAD-Asia initiative: leveraging yesterday’s data for tomorrow

Background

In clinical oncology, it is widely recognized that data sharing and the integration of completed clinical trials can promote research and development (R&D). The Foundation Aide et Recherche en Cancérologie Digestive (ARCAD) database project was initiated in Europe and the United States in 2006. Approximately 40 000 individual patient data (IPD) for metastatic colorectal cancer were collected and constructed as an integrated database.

Materials and methods

ARCAD-Asia was launched in 2021 and has been actively collecting Asian clinical trials. In addition, ARCAD-Asian data were periodically transferred to the Mayo Clinic, and IPD was integrated into the ARCAD database. Finally, all data were shared with three data centers, ARCAD-Asia and ARCAD, located in Europe, the United States, and Japan. We have developed a reproducible and reliable data conversion procedure based on the methodology established by ARCAD.

Results

From September 2021 to April 2023, 2318 IPD from four first-line, two second-line, and three third-line trials for metastatic colorectal cancer were integrated and stored in ARCAD-Asia. By autumn 2023, three more trials (1565 IPD) will be included, resulting in 12 trials (3883 IPD) in the Asia database. These are transferred and shared with ARCAD. After integrating Asian data, the ARCAD database contained 70 trials with ∼50 000 IPD.

Conclusions

Based on our active collaboration, ARCAD-Asia was established, and a global integrated database was constructed. As a next step, we will continue to collect Asian IPD and expand the cancer types, leading to a more comprehensive and available global database.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Gastric cancer hospital-based registry: real-world gastric cancer data from Latin America and Europe Geriatric Assessment-guided therapy modification and outcomes in patients with non-metastatic gastroesophageal cancer: a retrospective cohort study☆ Table of Contents Editorial Board PRABITAS study design: a pragmatic, randomized phase III trial of bi-weekly versus conventional trifluridine/tipiracil plus bevacizumab for metastatic colorectal cancer
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1